GlobeNewswireMAY 73 min read$PHAR

Pharming Group reports first quarter 2026 financial

Pharming Group reported its first quarter 2026 financial results, with total revenues decreasing by 8% to US$72.4 million compared to Q1 2025. While RUCONEST® revenue declined due to anticipated inventory drawdowns and market exits, Joenja® revenue grew by 34% to US$14.1 million, driven by strong patient uptake. The company reaffirmed its 2026 total revenue guidance and announced progress on Joenja®'s pediatric label expansion in the U.S. and launches in Japan and Europe.

Original reporting

GlobeNewswire

Published May 7, 2026, 5:08 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai May 7, 2026, 5:30 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Pharming Group reports first quarter 2026 financial — source image — Source · GlobeNewswire

Decision brief

The 30-second read

$PHARNeutralMed

Why it matters

The company's financial stability and growth prospects appear intact, supporting a cautiously optimistic trading stance.

Market read

The news is relevant for biotech investors, indicating potential opportunities and risks associated with Pharming Group and similar companies.

What to watch

Potential regulatory hurdles in Japan and Europe could impact future revenue growth; macroeconomic factors may influence market sentiment.

Timing: Immediate, given the recent earnings release and strategic updates.

Background

Pharming Group is a biotech company focusing on rare disease treatments, with recent strategic initiatives including product launches and pipeline expansion.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PHARNeutralMedium confidence

Context

The news pertains directly to Pharming Group's financial performance and strategic developments, making it highly relevant for trading decisions.

Expected impact

Minor upward movement in the short term, with potential for moderate gains if growth initiatives succeed.

Evidence & confidence

The mixed financial results and strategic updates suggest limited immediate volatility but positive long-term prospects if growth targets are met.

Market effects

Sector

The results highlight resilience in the biotech sector, especially companies with diversified product portfolios and pipeline progress.

Regional

Potential positive influence on biotech stocks in the U.S., Europe, and Japan due to expansion plans.

Global

Moderate, as the company's developments are part of broader industry trends in biotech innovation.

Counterpoint

What could challenge this read

Some investors may interpret the revenue decline as a warning sign of underlying challenges, advocating for a wait-and-see approach before increasing exposure.

Key entities

Company
Pharming Group
A biotech firm specializing in rare disease therapies.
Product
Joenja®
A treatment for myasthenia gravis with recent revenue growth.

Read at source ← All news

JUL 30

$PHARMedAI 8/10

Pharming Group cuts 2026 revenue guidance by $30m on weak sales By Investing.com

Pharming Group cut its 2026 revenue guidance by $30 million to $375 million to $395 million, citing weaker Q2 sales and continued weakness in its legacy Ruconest product. Q2 revenue was $90.2 million versus $100.8 million consensus. Ruconest sales fell 10% to $72.3 million, below $83.8 million. Operating profit was $1.3 million.

investing.com4 min

JUL 30

$PHARMedAI 8/10

Pharming Group N.V.: Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader ther

Pharming Group N.V. reported Q2 2026 total revenues of US$90.2m, down 3% year over year. RUCONEST revenue was US$72.3m, down 10% YoY, while Joenja (leniolisib) revenue rose to US$17.9m, up 40% YoY. Q2 operating profit fell to US$1.3m. The company revised 2026 revenue guidance to US$375m-395m and operating expense guidance to US$315m-320m.

finanznachrichten.de7 min

JUN 4

$BPMedAI 8/10

European Shares Edge Higher On Lebanon Ceasefire; FTSE 100 Dips As Energy Stocks Drag

European stocks rose slightly after Israel and Lebanon agreed to renew a fragile ceasefire, while oil prices fell more than 1% toward $96/bbl. STOXX 600 added 0.2% to 622.14; DAX +0.6% and CAC 40 +0.8%, but FTSE 100 -0.4% as BP and Shell dragged. Vivendi -4.6%; Remy Cointreau +11%; UMG -5.6%; CMC Markets +13%.

finanznachrichten.de4 min

JUN 4

$PHARMedAI 9/10

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

Pharming said the U.S. FDA accepted its resubmitted supplemental NDA for Joenja (leniolisib) to treat children ages 4–11 with APDS. After a Jan. 30, 2026 CRL and a March 26 Type A meeting, the sNDA seeks approval for 40 mg and 50 mg twice daily for patients ≥27 kg, with FDA requesting additional batch-testing analytical data. The PDUFA target action date is Oct. 24, 2026. A separate sNDA for lower-weight patients is planned for the second half of 2026.

manilatimes.net4 min

AUG 11

$PMed

Everpure Lands New Design Win with Second Top-Five Hyperscaler

Everpure (NYSE: P) said it secured a design win and supply agreement with a second top-five hyperscaler, building on a similar win announced in late 2024. The company attributes the deal to its DirectFlash technology for hyperscale storage. Everpure expects revenue contributions starting in fiscal 2028 and beyond.

itwire.com2 min